SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3511Without details it is hard to review what went wrong in ARRIVE. Maybe HIV associMiljenko Zuanic-2/15/2018
3510GLMD rebounding 20% today. Some investors may have conflated ARRIVE and ARREST sDewDiligence_on_SI-2/15/2018
3509Aramchol is large and "fat" compound, long shot, I am not sure it is rMiljenko Zuanic-2/14/2018
3508By not holding a CC today, GLMD is leaving the impression that investors are corDewDiligence_on_SI-2/14/2018
3507I think it is different, but doubt very much that Aramchol will show benefit in Miljenko Zuanic-2/14/2018
3506Yah, TTPH trading well below cash now. Is there something left? Rick knows bettuck-2/14/2018
3505Galmed (GLMD) also cut more than in half by missing the primary endpoint in its tuck-2/14/2018
3504<Let ALL BE GENERIC AT START!> And AMZN will work HARD to make it happenMiljenko Zuanic-2/14/2018
3503TTPH: ya, well I wasn't. Arrrg! Is there anything left here? ............SPRSteve Lokness-2/14/2018
3502So, who will pay for tax cut, expanded military spending and Infrastructure billMiljenko Zuanic-2/14/2018
3501Omeros (OMER) off 17% as another analysis piles onto Adam Feuerstein's thesituck-2/14/2018
3500Tetraphase (TTPH) more than cut in half as Eravacycline again fails, this time ituck-2/13/2018
3499AFMD down 16% today on financing. Could this be a buying opportunity? BladerunBladerunner17-2/13/2018
3498Not AXON. I like AVXL better. JuliusJulius Wong-2/12/2018
3497Axovant (AXON) down about 20% to fresh new lows on news of both CEO (highly hypetuck-2/12/2018
3496ENTA -16% on two sell-side downgrades (and general market malaise). There was nDewDiligence_on_SI-2/8/2018
3495Bellicum (BLCM) off 31% as I type on clinical hold of BPX-501 for the usual CAR-tuck-1/31/2018
3494Sure. MannKind (MNKD) off nearly 19% to low $3s after a senseless spike yesterdtuck11/26/2018
3493I think Ampligen has them all beat (>40 yrs in development); the latest: globDewDiligence_on_SI11/26/2018
3492Puma (PBYI) off 27% after hours as CHMP gives thumbs down for Neratinib. US lautuck-1/23/2018
3491Halozyme's (HALO) PEGPH20 combo with mFFOX did far worse on OS than mFFOX altuck-1/16/2018
3490How about Multikine?rkrw-1/9/2018
3489Axsome (AXSM) pain trial halted for futility, sending shares down 30%. A similatuck-1/9/2018
3488OHRP—Did any fake-drug candidate live longer? Possibly Bavituximab. My post-mortDewDiligence_on_SI-1/8/2018
3487Editas (EDIT) off 17% and other Crispr stocks (CRSP, NTLA) also weak after this tuck-1/8/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News